These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8807146)

  • 21. [Contribution of pharmacology for new drug application in Japan].
    Suzuki-Nishimura T; Toyoshima S; Uyama Y; Yamada H; Hosoki R; Fujimori K; Nagao T
    Nihon Yakurigaku Zasshi; 2002 Sep; 120(3):187-94. PubMed ID: 12271514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Reform of Japan's NTP and its technical perspectives].
    Mori T
    Kekkaku; 2004 Oct; 79(10):587-604. PubMed ID: 15631111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the Effectiveness of Repricing for Market Expansion in the Japanese Drug Pricing System.
    Shibata S; Uemura R; Suzuki T
    Ther Innov Regul Sci; 2016 Nov; 50(6):751-758. PubMed ID: 30231734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ICH E9 guideline 'Statistical principles for clinical trials': a case study.
    Phillips A; Haudiquet V
    Stat Med; 2003 Jan; 22(1):1-11; discussion 13-7. PubMed ID: 12486747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Performing clinical trials efficiently in Japan--independent clinical trials and GCP].
    Kanai M; Suzuki-Nishimura T
    Nihon Kokyuki Gakkai Zasshi; 2007 Jun; 45(6):449-54. PubMed ID: 17644939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experiences with GLP/GCP from the pharmaceutical industry's viewpoint.
    Legler UF
    Methods Find Exp Clin Pharmacol; 1993 May; 15(4):233-6. PubMed ID: 8361261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current problems of early phase clinical trials for new anticancer agents in Japan].
    Nakagawa K; Fukuoka M
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):925-9. PubMed ID: 10897223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot study to build a database on seven anti-hypertensive drugs.
    Fujita T; Miura Y; Mayama T
    Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):41-6. PubMed ID: 15534857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Status of the GCP guidelines in Europe.
    Geussenhainer S
    Methods Find Exp Clin Pharmacol; 1993 May; 15(4):223-8. PubMed ID: 8361259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacology and clinical trials in Japan.
    Ebihara A; Takahashi K; Ikemoto F; Yamamoto K
    J Mol Med (Berl); 1996 Aug; 74(8):479-86. PubMed ID: 8872862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug development history, "overview," and what are GCPs?
    Heilman RD
    Qual Assur; 1995 Mar; 4(1):75-9. PubMed ID: 8520867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Marketing Approval of Ethical Kampo Medicines].
    Hakamatsuka T
    Yakugaku Zasshi; 2017; 137(2):163-165. PubMed ID: 28154326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Doctor-initiated clinical trials and the revised pharmaceutical affairs law].
    Takano T; Saijo N
    Gan To Kagaku Ryoho; 2003 Oct; 30(10):1391-7. PubMed ID: 14584270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Participation to international registration trials--from the investigator's standpoint].
    Ohtsu A
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):297-300. PubMed ID: 17301548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chapter 1. A contemporary history of the Japanese pharmaceutical industry (1980-2010). A contemporary history of the Japanese Pharmaceutical Industry (1980-2010) Task Force].
    Yakushigaku Zasshi; 2014; 49(1):18-38. PubMed ID: 25272635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experiences with GCP in the pharmaceutical industry [corrected].
    Rämsch KD
    Methods Find Exp Clin Pharmacol; 1993 May; 15(4):237-40. PubMed ID: 8240533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. UK medicines policy: the role of clinical pharmacologists.
    Webb DJ
    Br J Clin Pharmacol; 2012 Jun; 73(6):948-52. PubMed ID: 22360620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In order to perform clinical trials efficiently in Japan--important issues regarding monitoring by sponsors].
    Kaichi S; Oda T; Goto K; Sato K
    Nihon Kokyuki Gakkai Zasshi; 2007 Nov; 45(11):829-35. PubMed ID: 18051783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Regulatory Trends in Pharmaceutical Manufacturing and their Impact on the Industry.
    Tabersky D; Woelfle M; Ruess JA; Brem S; Brombacher S
    Chimia (Aarau); 2018 Mar; 72(3):146-150. PubMed ID: 29631666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.